Arena Pharmaceuticals (NASDAQ: ARNA) issued its quarterly earnings data on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.07. The company had revenue of $1.94 million for the quarter, compared to the consensus estimate of $21.94 million.
Several analysts have also recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Arena Pharmaceuticals in a research note to investors on Wednesday, February 6th. They set an “outperform” rating and a $12.00 price target on the stock. They noted that the move was a valuation call. On a related note, analysts at TheStreet reiterated a “sell” rating on shares of Arena Pharmaceuticals in a research note to investors on Monday, January 28th. Finally, analysts at TheStreet reiterated a “sell” rating on shares of Arena Pharmaceuticals in a research note to investors on Thursday, December 27th.
Three equities research analysts have rated the stock with a buy rating, five have assigned a hold rating, and one has given a sell rating to the company. The company presently has a consensus rating of “hold” and a consensus price target of $9.60.
Shares of Arena Pharmaceuticals (ARNA) opened at 8.34 on Monday. Arena Pharmaceuticals (ARNA) has a 52 week low of $1.70 and a 52 week high of $13.50. The stock’s 50-day moving average is currently $8.76. The company’s market cap is $1.812 billion.
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
You call Farstain an analyst? He is not an analyst and doesn’t have any qualifications for being called an analyst.